rs9340799 — ESR1 XbaI polymorphism

ESR1 XbaI — How This Estrogen Receptor Variant Shapes Reproductive Outcomes

Estrogen receptor alpha (ERα), encoded by ESR1 on chromosome 6, is the master mediator of estrogen signaling across reproductive tissues, bone, brain, and the cardiovascular system. When estrogen binds ERα, the receptor dimerizes, translocates to gene promoters, and drives transcription of hundreds of downstream targets governing menstrual cyclicity, endometrial receptivity, follicular growth, and uterine function. The rs9340799 XbaI polymorphism — an A-to-G substitution deep in the first intron of ESR1 — does not change the receptor's amino acid sequence, but accumulating evidence suggests it influences receptor expression levels and estrogen-signaling efficiency in reproductive tissues.

The variant earned its name from the restriction enzyme XbaI: the A allele creates a recognition site that is cut by XbaI, while the G allele abolishes this site. Because it sits in an intron and has been studied extensively by RFLP genotyping, the literature uses two parallel naming conventions — the "XbaI A/G" allele system (used here, as it corresponds to the plus-strand GRCh38 alleles) and the older "X/x" uppercase/lowercase notation where uppercase X denotes absence of the restriction site (the G allele).

The Mechanism

rs9340799 lies within intron 1 of ESR1, a region that contains regulatory elements influencing transcription and alternative splicing. The A>G change is in strong linkage disequilibrium¹¹ linkage disequilibrium
LD means the two variants are inherited together so often that knowing one predicts the other with the adjacent PvuII polymorphism (rs2234693), and both are typically analyzed as a haplotype. The G allele at rs9340799 disrupts predicted regulatory motifs and appears to reduce baseline ERα expression in endometrial tissue relative to the A allele, which may alter estrogen sensitivity during the implantation window.

The precise molecular mechanism remains incompletely characterized. The variant may act through altered splicing efficiency, effects on enhancer activity, or changes to the local chromatin environment. Crucially, the same G allele that reduces endometrial estrogen responsiveness may paradoxically protect against bone fractures (potentially via altered bone-specific ERα isoform expression) and against male infertility — illustrating how tissue-specific regulatory effects can produce direction-switching outcomes across biological contexts.

The Evidence

Endometriosis and IVF outcomes: A Brazilian case-control study (98 endometriosis patients, 115 IVF-failure patients, 134 fertile controls)²² Brazilian case-control study (98 endometriosis patients, 115 IVF-failure patients, 134 fertile controls)
Paskulin et al. Disease Markers, 2013 found that the GG genotype was strongly associated with endometriosis-related infertility (OR 4.67, 95% CI 1.84–11.83, P = 0.001) and with IVF failure (OR 3.33, 95% CI 1.38–8.03, P = 0.007). In the same cohort, the AA genotype was significantly more common in fertile controls, suggesting the A allele supports normal endometrial function.

Consistent with this, a cross-sectional IVF study of 136 Brazilian infertile women³³ cross-sectional IVF study of 136 Brazilian infertile women
de Mattos et al. Journal of Ovarian Research, 2014 found the AA genotype was associated with significantly more follicles, more mature oocytes, and better embryo quality during controlled ovarian hyperstimulation — suggesting the A allele confers superior ovarian responsiveness to FSH stimulation.

Premature ovarian insufficiency: An Iranian case-control study (150 POI cases, 150 controls under age 35)⁴⁴ Iranian case-control study (150 POI cases, 150 controls under age 35)
Eshaghi et al. International Journal of Reproductive Biomedicine, 2022 found significant associations between rs9340799 genotypes and premature ovarian insufficiency. The T(PvuII)/A(XbaI) haplotype (i.e., carrying the rs2234693 T allele with the rs9340799 A allele) was identified as a risk haplotype for POI, suggesting complex genotype × context effects at this locus.

Severe pre-eclampsia: A meta-analysis of seven studies⁵⁵ meta-analysis of seven studies
Zhao et al. Bioscience Reports, 2019 found the GG genotype was associated with elevated severe pre-eclampsia risk (OR 1.67, 95% CI 1.10–2.25, P = 0.017), while neither genotype was associated with mild pre-eclampsia. The evidence is modest given the small number of constituent studies and limited statistical power.

Fractures: The large GENOMOS consortium study of 18,917 individuals across eight European centers⁶⁶ GENOMOS consortium study of 18,917 individuals across eight European centers
Ioannidis et al. JAMA, 2004 found that the GG genotype (absent XbaI site) was associated with a 19% reduction in all fractures (OR 0.81, P = 0.002) and a 35% reduction in vertebral fractures (OR 0.65, P = 0.003) — an effect independent of bone mineral density. This is a protective effect of the G allele that contrasts with its reproductive-tissue risk profile.

Breast cancer: A meta-analysis of 34,721 subjects across 23 studies⁷⁷ meta-analysis of 34,721 subjects across 23 studies
Tan et al. Scientific Reports, 2021 found no significant association between rs9340799 and breast cancer risk across all genetic models tested, settling a previously contested question.

Practical Implications

For women, the strongest clinically actionable signals from rs9340799 are in the reproductive domain: the GG genotype is associated with elevated endometriosis-related infertility risk and IVF failure, and with greater severe pre-eclampsia susceptibility. Heterozygous AG carriers show intermediate risk. The AA genotype is associated with better ovarian responsiveness during IVF stimulation.

Women carrying the GG genotype who are planning pregnancy should discuss their genetic profile with a reproductive specialist, particularly if IVF is anticipated. Early referral and personalized FSH dosing protocols informed by this variant may improve controlled ovarian hyperstimulation outcomes. GG carriers with symptoms suggestive of endometriosis warrant proactive evaluation rather than symptom normalization.

For men, the G allele appears protective against infertility, suggesting sex-specific regulatory effects on the reproductive axis.

Interactions

rs2234693 (ESR1 PvuII): rs9340799 and rs2234693 are in strong linkage disequilibrium and are most informative as a haplotype. The C(PvuII)/G(XbaI) haplotype was associated with approximately 5-fold elevated coronary artery disease risk in one Indian case-control study. For reproductive outcomes, the T/A haplotype (rs2234693 T + rs9340799 A) appears relevant to premature ovarian insufficiency. Compound action proposal: women carrying both rs2234693 TT and rs9340799 GG genotypes may represent a subgroup with elevated reproductive vulnerability warranting earlier fertility workup; evidence level moderate.

rs2046210 (ESR1 promoter): A 2024 study found rs2046210 GA heterozygosity significantly increased endometriosis risk and elevated ESR1 expression in eutopic endometrium, suggesting that multiple ESR1 regulatory variants contribute independently to endometriosis susceptibility. Women carrying risk alleles at both rs9340799 and rs2046210 may have compounded estrogen-signaling dysregulation.

rs7521902 (near WNT4): WNT4 signaling suppresses androgen production and supports female reproductive development; its GWAS locus is one of the most replicated endometriosis signals. Carrying risk alleles at both ESR1 and WNT4 loci may confer additive endometriosis susceptibility, though formal interaction testing has not been published.